News >

Alternative Treatment Options Emerging for Relapsed Pediatric Patients With ALL

Danielle Bucco
Published: Monday, Nov 27, 2017

Susan R. Rheingold, MD

Susan R. Rheingold, MD
The September 2017 FDA approval of tisagenlecleucel (Kymriah), the chimeric antigen receptor (CAR) T-cell therapy, has already made a significant impact on pediatric patients with acute lymphoblastic leukemia (ALL).

, Rheingold, medical director of the Oncology Outpatient Clinic, physician with the Cancer Center at Children’s Hospital of Philadelphia, discusses the impact of CAR T-cell therapy on patients with ALL and options for patients who relapse on treatment.

OncLive: What is the role of CAR T-cell therapy in pediatric ALL?

Rheingold: CAR T-cell therapy is not yet approved for upfront treatment. However, for relapsed disease, it has made a significant change in the number of children it will put back into remission and ultimately cure. It is probably the most promising new cancer therapy in a long time for any type of cancer. However, it is not a frontline therapy for newly diagnosed children; therefore, it will not be replacing frontline chemotherapy just yet.

Are there any other regimens in the pipeline that are showing a similar impact?

It is better to have relapsed ALL now rather than 10 years ago, because there is a whole class of immunotherapy drugs that are altering the treatment paradigm.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication
x